COMPANY PROFILE // THE 014 REPORT
Surrozen, Inc./DE
SRZN (Nasdaq) · Formerly: Consonance-HFW Acquisition Corp.
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Surrozen, Inc./DE is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in South San Francisco, CA; listed as SRZN (Nasdaq).[source] It reported revenue of $3.5 million for the fiscal year ended 2025-12-31.[source] It has filed 99 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13D/A, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are TCG Crossover Management, LLC, Boxer Capital Management, LLC, Kalehua Capital Management LLC (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- TCG Crossover Management, LLC$38.2M
- Boxer Capital Management, LLC$27.0M
- Kalehua Capital Management LLC$20.0M
- MILLENNIUM MANAGEMENT LLC$17.7M
- Point72 Asset Management, L.P.$17.2M
- Venrock Adviser, LLC$16.4M
- STEMPOINT CAPITAL LP$13.8M
- PERCEPTIVE ADVISORS LLC$13.1M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Li Yang · Exec. Vice President, Research (Officer) · latest Form 4 2026-02-18 · filing · LinkedIn search
- Maleki Andrew Pedrum · Chief Financial Officer (Officer) · latest Form 4 2025-11-13 · filing · LinkedIn search
- Parker Craig C · Chief Executive Officer (Director,Officer) · latest Form 4 2026-02-18 · filing · LinkedIn search
- Williams Charles O · Chief Operating Officer (Officer) · latest Form 4 2026-02-18 · filing · LinkedIn search
- BJERKHOLT ERIC · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- Berkenblit Anna · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- CHAI CHRISTOPHER Y · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- Haak-Frendscho Mary · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- Kutzkey Tim · Director,10% owner · latest Form 4 2026-01-20 · filing · LinkedIn search
- Lin Shao-Lee · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- Rothenberg Mace · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
- WOODHOUSE DAVID J · Director · latest Form 4 2025-05-15 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- John T. McKenna John T. McKenna Cooley LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-23
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001824893 | source |
| EIN | 30-1374889 | source |
| Business address (SEC) | 171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (3)
- Maze Therapeutics, Inc. · SEC registrant
- Tenaya Therapeutics, Inc. · SEC registrant
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- CERUS CORP · BJERKHOLT ERIC
- Mirum Pharmaceuticals, Inc. · BJERKHOLT ERIC
- Metagenomi Therapeutics, Inc. · BJERKHOLT ERIC
- Tango Therapeutics, Inc. · Rothenberg Mace
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-18 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-11-18 filing S-3 · SEC EDGAR
- 2026-11-16 filing 424B5 · SEC EDGAR
- 2026-11-16 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-11-13 filing FWP · SEC EDGAR
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-06 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-10-22 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-10-20 filing 8-K items 2.02,3.02,9.01 · SEC EDGAR
- 2026-10-02 filing 8-K items 8.01 · SEC EDGAR
- 2026-08-07 filing 25-NSE · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02 · SEC EDGAR
- 2026-05-18 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-14 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-01 filing ARS · SEC EDGAR
- 2026-04-01 filing DEFA14A · SEC EDGAR
- 2026-04-01 filing Proxy statement · SEC EDGAR
- 2026-03-30 filing EFFECT · SEC EDGAR
- 2026-03-30 filing 424B5 · SEC EDGAR
- 2026-03-27 filing CORRESP · SEC EDGAR
- 2026-03-27 filing UPLOAD · SEC EDGAR
- 2026-03-23 filing S-8 · SEC EDGAR
- 2026-03-23 filing S-3 · SEC EDGAR
- 2026-03-23 filing Annual report (10-K) · SEC EDGAR
- 2026-03-23 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-30 officer change 8-K items 5.02 · SEC EDGAR
170 earlier entries
- 2026-01-22 filing SCHEDULE 13D/A
- 2025-12-02 insider First Form 3/4/5 on record for Kutzkey Tim (Director,10% owner)
- 2025-11-13 insider First Form 3/4/5 on record for Maleki Andrew Pedrum (Chief Financial Officer)
- 2025-11-07 filing Quarterly report (10-Q)
- 2025-11-07 officer change 8-K items 2.02,5.02
- 2025-10-17 filing 8-K items 1.02
- 2025-08-29 filing 8-K items 1.01,9.01
- 2025-08-29 filing 424B5
- 2025-08-08 filing S-8
- 2025-08-08 filing Quarterly report (10-Q)
- 2025-08-08 filing 8-K items 2.02,9.01
- 2025-05-23 filing EFFECT
- 2025-05-21 filing CORRESP
- 2025-05-21 filing UPLOAD
- 2025-05-20 filing S-3
- 2025-05-15 filing 8-K items 5.07
- 2025-05-15 insider First Form 3/4/5 on record for BJERKHOLT ERIC (Director)
- 2025-05-15 insider First Form 3/4/5 on record for Berkenblit Anna (Director)
- 2025-05-15 insider First Form 3/4/5 on record for CHAI CHRISTOPHER Y (Director)
- 2025-05-15 insider First Form 3/4/5 on record for Haak-Frendscho Mary (Director)
- 2025-05-15 insider First Form 3/4/5 on record for Lin Shao-Lee (Director)
- 2025-05-15 insider First Form 3/4/5 on record for Rothenberg Mace (Director)
- 2025-05-15 insider First Form 3/4/5 on record for WOODHOUSE DAVID J (Director)
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-09 filing 8-K items 2.02,9.01
- 2025-05-05 insider First Form 3/4/5 on record for Li Yang (Exec. Vice President, Research)
- 2025-05-05 insider First Form 3/4/5 on record for Parker Craig C (Chief Executive Officer)
- 2025-05-05 insider First Form 3/4/5 on record for Williams Charles O (Chief Operating Officer)
- 2025-05-01 filing EFFECT
- 2025-05-01 filing 424B5
- 2025-04-29 filing CORRESP
- 2025-04-29 filing UPLOAD
- 2025-04-24 filing 424B5
- 2025-04-23 filing S-3
- 2025-04-08 filing D
- 2025-04-02 filing ARS
- 2025-04-02 filing DEFA14A
- 2025-04-02 filing Proxy statement
- 2025-03-31 filing S-8
- 2025-03-31 filing Annual report (10-K)
- 2025-03-31 filing 8-K items 2.02,9.01
- 2025-03-28 filing SCHEDULE 13D/A
- 2025-03-28 officer change 8-K items 1.01,3.02,5.02,9.01
- 2025-03-24 filing 8-K items 7.01,9.01
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02
- 2024-10-02 filing 8-K items 1.01,9.01
- 2024-08-12 filing Quarterly report (10-Q)
- 2024-08-12 filing 8-K items 2.02
- 2024-07-01 officer change 8-K items 5.02
- 2024-06-07 filing 8-K items 5.07
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02
- 2024-04-25 filing EFFECT
- 2024-04-25 filing 424B5
- 2024-04-23 filing CORRESP
- 2024-04-23 filing ARS
- 2024-04-23 filing DEFA14A
- 2024-04-23 filing Proxy statement
- 2024-04-23 filing UPLOAD
- 2024-04-19 filing D
- 2024-04-18 filing S-3
- 2024-04-17 filing SC 13D/A
- 2024-04-10 filing S-8
- 2024-04-10 filing Annual report (10-K)
- 2024-04-08 filing SC 13D/A
- 2024-04-02 filing 8-K items 1.01,3.02,9.01
- 2024-04-02 filing NT 10-K
- 2024-04-01 filing 8-K items 7.01,9.01
- 2024-02-07 filing 424B3
- 2024-02-07 officer change 8-K items 5.02
- 2024-01-22 filing 424B3
- 2024-01-18 filing 8-K items 8.01
- 2023-12-13 filing 424B3
- 2023-12-13 filing 8-K items 5.03
- 2023-12-11 filing 424B3
- 2023-12-11 filing 8-K items 5.07,8.01
- 2023-11-08 filing 424B3
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-08 filing 8-K items 2.02
- 2023-10-24 filing DEFA14A
- 2023-10-24 filing Proxy statement
- 2023-10-13 filing PRE 14A
- 2023-10-13 filing 8-K items 5.03
- 2023-08-09 filing 424B3
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-09 filing 8-K items 2.02,9.01
- 2023-07-19 officer change 8-K items 5.02,9.01
- 2023-07-05 filing 8-K items 3.01
- 2023-05-22 filing 8-K items 5.07,9.01
- 2023-05-10 filing 424B3
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-10 filing 8-K items 2.02,9.01
- 2023-04-07 filing 424B3
- 2023-04-07 filing 424B3
- 2023-04-06 filing EFFECT
- 2023-04-06 filing ARS
- 2023-04-06 filing DEFA14A
- 2023-04-06 filing Proxy statement
- 2023-04-06 filing 424B3
- 2023-04-05 filing EFFECT
- 2023-04-05 officer change 8-K items 5.02
- 2023-03-31 filing POS AM
- 2023-03-31 filing 424B5
- 2023-03-31 filing POS AM
- 2023-03-31 filing S-8
- 2023-03-31 filing Annual report (10-K)
- 2023-03-23 filing 424B3
- 2023-03-23 filing 424B3
- 2023-03-23 filing 8-K items 8.01
- 2023-03-22 filing 8-K items 2.02,9.01
- 2023-02-13 filing SC 13D/A
- 2023-01-05 filing 424B3
- 2023-01-05 filing 424B3
- 2023-01-05 filing 8-K items 3.01
- 2022-12-21 filing 424B5
- 2022-12-19 filing EFFECT
- 2022-12-15 filing CORRESP
- 2022-12-15 filing UPLOAD
- 2022-12-15 filing SC 13D/A
- 2022-12-15 filing 424B3
- 2022-12-15 filing 424B3
- 2022-12-15 filing 8-K items 8.01
- 2022-12-09 filing S-3
- 2022-11-16 filing 8-K items 2.02,9.01
- 2022-11-15 filing 424B3
- 2022-11-15 filing 424B3
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-10-06 filing 8-K items 1.01
- 2022-08-25 filing 424B3
- 2022-08-23 filing 424B3
- 2022-08-11 filing Quarterly report (10-Q)
- 2022-08-11 filing 8-K items 2.02,9.01
- 2022-06-14 filing 8-K items 5.07,9.01
- 2022-05-12 filing 424B3
- 2022-05-12 filing 424B3
- 2022-05-11 filing Quarterly report (10-Q)
- 2022-05-11 filing 8-K items 2.02,9.01
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-04-05 filing EFFECT
- 2022-04-05 filing 424B3
- 2022-04-01 filing CORRESP
- 2022-04-01 filing UPLOAD
- 2022-03-31 filing 424B3
- 2022-03-29 filing EFFECT
- 2022-03-29 filing S-8
- 2022-03-29 filing Registration (S-1)
- 2022-03-29 filing POS AM
- 2022-03-28 filing Annual report (10-K)
- 2022-03-24 filing 8-K items 2.02,5.08,9.01
- 2022-02-24 filing 424B3
- 2022-02-24 filing 8-K items 1.01,3.02,9.01
- 2022-01-10 filing 424B3
- 2022-01-10 filing 8-K items 8.01
- 2021-11-16 filing 424B3
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-11-15 filing 8-K items 2.02,9.01
- 2021-11-10 filing 424B3
- 2021-11-09 filing EFFECT
- 2021-11-08 filing CORRESP
- 2021-11-08 filing S-1/A
- 2021-11-08 filing S-8
- 2021-09-29 filing SC 13D/A
- 2021-09-27 filing UPLOAD
- 2021-09-13 filing Registration (S-1)
- 2021-08-23 filing SC 13D
- 2021-08-20 filing 3/A
- 2021-08-20 filing 3/A
- 2021-08-20 filing 3/A
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-18 (within 7 days) S-3 filed
- 2026-11-16 (within 7 days) 424B5 filed
- 2026-11-16 (within 7 days) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-11-13 (within 30 days) FWP filed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 (older) 8-K filed: Item 2.02 results of operations; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-10-02 (older) 8-K filed: Item 8.01 other event
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SRZN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1824893 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SRZN / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 301374889 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001824893 | SEC EDGAR / IRS |
| CUSIP | 86889P208 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001824893 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $3,477,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 10:55 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$242,026,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:55 UTC | Report an error |
| Total assets (at 2025-12-31) | $98,726,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:55 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$187,762,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:55 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $89,245,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:55 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
| State of incorporation | DE | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
| Business address | 171 OYSTER POINT BLVD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 10:55 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$30,244,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:55 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $128,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:55 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $6,639,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 10:55 UTC | Report an error |
| Form D total offering amount (D filed 2025-04-08) | $174,999,955 | 2025-04-08 | D | as filed | 2026-11-20 10:55 UTC | Report an error |
| Form D total amount sold (D filed 2025-04-08) | $76,402,277 | 2025-04-08 | D | as filed | 2026-11-20 10:55 UTC | Report an error |
| Form D industry group | Biotechnology | 2025-04-08 | D | as filed | 2026-11-20 10:55 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2025-04-08 | D | as filed | 2026-11-20 10:55 UTC | Report an error |
| Form D date of first sale | 2025-03-26 | 2025-04-08 | D | as filed | 2026-11-20 10:55 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453790
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453790 | 2026-11-20 10:55 UTC | Report an error |
| Net income (loss) | -$129,724,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453790 | 2026-11-20 10:55 UTC | Report an error |
| Cash and cash equivalents | $100,353,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453790 | 2026-11-20 10:55 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-18 Filing S-3 filed
- 2026-11-16 Filing 424B5 filed
- 2026-11-16 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-11-13 Filing FWP filed
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 Filing 8-K filed: Item 2.02 results of operations; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-10-02 Filing 8-K filed: Item 8.01 other event
- 2026-08-07 Filing 25-NSE filed
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations
- 2026-05-14 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-06 Filing 10-Q filed
- 2026-05-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-01 Filing ARS filed
- 2026-04-01 Filing DEFA14A filed
- 2026-04-01 Filing DEF 14A filed
- 2026-03-30 Filing EFFECT filed
- 2026-03-30 Filing 424B5 filed
- 2026-03-27 Filing CORRESP filed
- 2026-03-27 Filing UPLOAD filed
- 2026-03-23 Filing S-8 filed
- 2026-03-23 Filing S-3 filed
- 2026-03-23 Filing 10-K filed
- 2026-03-23 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-11-16 8-K Item 1.01, Entry into a Material Definitive Agreement
On November 13, 2026, Surrozen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 1,894,540 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $31.67 per share. All of the Shares in the Offering are being sold by the Company. The gross proceeds from the Offering are expected to be approximately $60 million before deducting underwriting discounts and commissions and other offering expenses payable by the… the 8-K · retrieved 2026-11-20 10:55 UTC - 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including the exhibit referenced herein) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended. the 8-K · retrieved 2026-11-20 10:55 UTC - 2026-10-20 8-K Item 2.02, Results of Operations and Financial Condition
On October 20, 2026, Surrozen, Inc. (the “Company”) issued a press release announcing certain financial results related to the Second Closing (as defined below). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this “Item 2.02. Results of Operations and Financial Condition” (including the exhibit referenced herein) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”). the 8-K · retrieved 2026-11-20 10:55 UTC - 2026-10-20 8-K Item 3.02, Unregistered Sales of Equity Securities
On October 20, 2026, the Company completed the second tranche closing (the “Second Closing”) under that certain Securities Purchase Agreement, dated March 24, 2025 (the “Purchase Agreement”), with certain institutional and accredited investors (the “Purchasers”) relating to the issuance and sale to the Purchasers of 5,741,605 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), pre-funded warrants (“Pre-Funded Warrants”) to purchase 2,456,500 shares of Common Stock, and warrants to purchase 4,099,052 shares of Common Stock (“Series E Common Warrants”). The Second Closing was contingent upon the public announcement of the receipt of clearance… the 8-K · retrieved 2026-11-20 10:55 UTC - 2026-10-02 8-K Item 8.01, Other Events
On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The IND went into effect following the completion of the statutory 30-day review period. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema (DME). We expect to dose the first patient in DUET, a Phase 1b/2a clinical study evaluating SZN-8141 in patients with DME, in the fourth quarter of 2026, with initial data expected in the… the 8-K · retrieved 2026-11-20 10:55 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | $38,226,971 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 2 | Boxer Capital Management, LLC | $26,963,591 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 3 | Kalehua Capital Management LLC | $19,990,738 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 4 | MILLENNIUM MANAGEMENT LLC | $17,725,900 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 5 | Point72 Asset Management, L.P. | $17,237,858 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 6 | Venrock Adviser, LLC | $16,424,559 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 7 | STEMPOINT CAPITAL LP | $13,786,568 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 8 | PERCEPTIVE ADVISORS LLC | $13,078,411 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 9 | Spruce Street Capital LP | $11,211,438 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
| 10 | BlackRock, Inc. | $10,246,721 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:55 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1824893.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001824893. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.